Hi @Rewop. I don’t think this has played out as any MSB shareholder would have thought. GVHD for example, I think different rules or a new vibe came into play. Out of MSBs & SI’s control. In hindsight maybe some things could have been done differently but then this is all such new medicine and if it is such a paradigm shift, perhaps the process to FDA approval also requires a paradigm shift.
I personally think SI is not your average CEO in that money is not his top priority; that doesn’t mean he does not know the value of money. Some people in officialdom may not fully appreciate this in a CEO.
Moving forward, I agree with you that a partnership with a company such as Novartis can only add insight & management expertise.
MSB Trading 2021 - paradigm shift, page-197
-
- There are more pages in this discussion • 10,014 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 94461 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 61151 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |